Introduction {#s1}
============

The zebrafish (*Danio rerio*) model has proven to be an invaluable tool in multiple areas of research, such as development and toxicology ([@B14]; [@B55]; [@B18]). The anatomy and physiology of fish is homologous to humans ([@B1]); 84% of human disease-related genes are present in the zebrafish genome and about 70% of human genes have a zebrafish ortholog ([@B27]). The zebrafish has been used as a model to elucidate the molecular mechanisms responsible for 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) toxicity ([@B25]). In zebrafish, developmental exposure to TCDD causes impaired reproductive development, embryonic lethality, and/or severe developmental defects in several tissues, including heart, cartilage, and vasculature (reviewed in [@B10]).

TCDD toxicity is mediated through the aryl hydrocarbon receptor (AHR) (reviewed in [@B8]). The AHR is a conserved receptor from invertebrates to vertebrates and is the only ligand-activated member of the basic helix-loop-helix PER-ARNT-SIM protein family ([@B22]; [@B24]). The AHR can be activated by many environmental contaminants, including chlorinated dioxins, biphenyls, and polyaromatic hydrocarbons ([@B37]; [@B62]). Upon activation, AHR dimerizes with ARNT, translocates to the nucleus, and induces ligand-specific transcriptional changes ([@B8]; [@B19]). In zebrafish, AHR2 and ARNT1 are the functional orthologs of mammalian AHR and ARNT, and loss of either protein protects against TCDD-induced toxicity phenotypes, including cardiac malformation, cartilage malformation, and reduced peripheral blood flow ([@B6]; [@B49]).

Identification of the downstream molecular targets responsible for specific endpoints of AHR-dependent toxicity remain largely unknown; however, in zebrafish, *sox9b* has been identified as one of the most reduced transcripts in several AHR2 toxicity target organs ([@B5], [@B4]; [@B64]; [@B26]). In zebrafish, an ancient genome duplication in the teleost lineage resulted in two *Sox9* co-orthologs (*sox9a* and *sox9b*), which have undergone subfunction partitioning with both distinct and overlapping functions ([@B48]; [@B65]). *Sox9* is required for proper vertebrate embryonic development by specifying cell fate and differentiation in linages from all three germ layers ([@B3], [@B2]; [@B23]; [@B53]; [@B56]; [@B17]).

*Sox9b* is hypothesized to have a causal role in cartilage and heart TCDD-induced toxicity phenotypes in zebrafish. Antisense knockdown of *sox9b* was sufficient to produce the TCDD-like jaw phenotype, and TCDD-exposed zebrafish embryos injected with *sox9b* mRNA rescued the TCDD-induced jaw malformations ([@B64]). TCDD exposure markedly reduces the expression of *sox9b* in zebrafish heart ventricles, and genetic ablation of *sox9b* results in TCDD-like heart malformations ([@B26]). The [@B64] and [@B26] studies indicate that the reduction in *sox9b* expression is partially responsible for the TCDD-induced cartilage and heart malformation phenotypes. While eight putative AHR elements are located within 5 kb of the *sox9b* transcriptional start site, *sox9b* downregulation does not occur until 4 hours after AHR2 activation, suggesting *sox9b* is not a direct AHR2 target gene ([@B64]). The mechanisms by which AHR2 activation leads to a reduction in *sox9b* expression and subsequent target organ toxicity are unknown.

Long noncoding RNAs (lncRNAs) are defined as transcripts equal to or greater than 200 nucleotides that do not appear to encode a protein. Genetic and biochemical evidence suggests that a primary role for lncRNAs is the regulation of epigenetic processes, most likely by guiding chromatin-modifying enzymes to their target sites and by acting as a platform for chromosomal organization and protein complexes ([@B51]). lncRNAs have been implicated in an array of biologic processes, including embryonic viability, development, response to stress, and cancer metastasis ([@B21]; [@B16]).

An important question left unanswered is how AHR2 activation by an exogenous ligand leads to the reduction of *sox9b* expression. We used the zebrafish model to probe the relationship between AHR2, a novel lncRNA (*slincR*), and *sox9b*. *SlincR* is located adjacent to the *sox9b* gene locus, and *slincR* expression was increased by a strong AHR ligand, which led us to test the hypothesis that *slincR* is regulated by AHR2 and is required for proper *sox9b* expression levels.

Materials and Methods {#s2}
=====================

All gene-specific primers, in situ probes, and antibody information is listed in ([Supplemental Table 1](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.117.108233/-/DC1)).

 {#s3}

### Fish Husbandry. {#s4}

Tropical 5D (wild-type) and *Tg*(*−2421/+29sox9b:EGFP*~uw2~) *sox9b* reporter strains of zebrafish (*Danio rerio*) were reared according to the Institutional Animal Care and Use Committee protocols at the Sinnhuber Aquatic Research Laboratory, Oregon State University. Adult fish were raised in a recirculating water system (28°C ± 1°C) with a 14-hour:10-hour light-dark schedule. Spawning and embryo collection were conducted as described in [@B63].

### Waterborne Exposure. {#s5}

Shield-stage \[∼6 hours post fertilization (hpf)\] embryos were exposed to 1 ng/ml TCDD (311 nM, 95.3% purity; SUPELCO Solutions Within, Bellfonte, PA) or vehicle \[0.1% dimethylsulfoxide (DMSO)\] with gentle rocking for 1 hour in 20-ml glass vials (10 embryos/ml). Vials were also gently inverted every 15 minutes to ensure proper mixing. After the exposure, embryos were rinsed three times with fish water and then raised in 100-mm petri dishes. We developmentally exposed embryos to 10 *µ*M benz(*a*)anthracene-7-12-dione (B\[*a*\]AQ) as previously described in [@B19].

### 5′ and 3′ Rapid Amplification of cDNA Ends. {#s6}

The FirstChoice RLM-RACE kit was performed as recommended by the manufacturer (Thermo Fisher; Eugene, OR). RNA was isolated at 48 hpf from whole embryos and cDNA was synthesized as described subsequently. Sanger sequencing was performed by the Core Facilities of the Center for Genome Research and Biocomputing at Oregon State University using an ABI 3730 capillary sequence machine (Thermofisher Scientific, Waltham, MA).

### Embryo Homogenization and Subcellular Fractionation. {#s7}

Approximately 50--60 embryos at 4 days post fertilization were homogenized with a 2-ml dounce homogenizer and tight pestle, and fractionated with a glucose gradient and centrifugation as detailed in [@B9]. The homogenization solutions followed the recipes described in [@B54]. For each cellular compartment, total RNA was isolated and cDNA was synthesized and quantified as described subsequently; however, only 2 ng of cDNA was used per reaction, the samples were not normalized to a reference gene, and whole embryo homogenate served as the calibrator. The samples analyzed consisted of three biologic replicates and two technical replicates, and *U1* rRNA served as a positive control for nuclear enrichment.

### Selective 2′-Hydroxyl Acylation Analyzed by Primer Extension (SHAPE). {#s8}

Details of the experimental methods are summarized in [@B35]. Wild-type RNA reference ladders were created using 3′dideoxy-TTP in an equilmolar amount to dTTP during the reverse transcription reaction. The SHAPE data were analyzed using HiTRACE-WEB ([@B34]). Replicates from three independent samples were compared, and we performed a signal decay correction step to normalize for the typical exponential decay in fluorescent intensity as a function of elution time ([@B31]). We normalized each point by dividing by the average intensity of positions later in elution time (earlier in nucleotide position) rather than using the sum because in practice the sum overcorrected for the signal decay. We then averaged the replicates and computed the probability of an adduct by subtracting the scaled average DMSO from the average *N*-methylisatoic anhydride signal to remove background noise ([@B31]). We fit the data to a normal distribution and capped the data above the 90th percentile to control any signal that was likely due to saturation. Finally, we scaled the data to be between 0 and 2 ([@B60]; [@B31]). The secondary structure was computed with the RNAfold WebServer (<http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi>), excluding isolated pairs, using dangling energies on both sides of the helices, and the Turner 2004 energy parameters ([@B59]; [@B41]). Folding was performed at 24°C, in accordance with experimental conditions, and SHAPE reactivities were used in the calculation using the Deigan algorithm with default parameters ([@B13]).

### Morpholino Injection. {#s9}

Approximately 2 nl total volume of a 1 mM solution of each morpholino (MO) were microinjected into the yolk of wild-type 5D and *sox9b*-eGFP reporter embryos at the one-cell stage. To test the effect of knocking down *slincR* expression levels, a splice blocking MO targeting the exon/intron boundary of *slincR* exon 1 (*slincR*-MO: 5′ GAC CTA AAC TCG ACC TTA CCA GAT C 3′) and a standard negative control (ConMO: 5′ CCT CTT ACC TCA GTT ACA ATT TAT A 3′) were obtained from GeneTools (Philomath, OR). Two methods were used to validate knockdown efficiencies: 1) total RNA was isolated and cDNA was synthesized and quantified, and/or 2) in situ hybridization was performed using a *slincR* probe (both detailed subsequently).

### RNA Extraction and mRNA Quantification. {#s10}

Total RNA was extracted from 48 hpf whole embryos using RNAzol (Molecular Research Center, Inc., Cincinnati, OH) and a bullet blender with 0.5 mM zirconium oxide beads (Next Advance, Averill Park, NY) as recommended by the manufacturer. RNA quality and quantity were assessed using a SynergyMix microplate reader with a Gen5 Take3 module (BioTek, Winooski, VT). Each biologic sample consisted of 20 embryos with a minimum of three biologic replicates per condition. Total RNA (1 *µ*g) was reverse transcribed into cDNA with random primers using the ABI High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher). Quantitative real-time polymerase chain reaction (PCR) was performed using a StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA). The 20 *µ*l reactions consisted of 10 *µ*l 2X SYBR Green Master Mix (Roche, Pleasanton, CA), 0.4 *µ*l each of 10 *µ*M forward and reverse primers, and 20 ng cDNA. The expression values were normalized to *β*-actin and analyzed with the 2^−ΔΔCT^ method as described in [@B40]. The results were statistically analyzed using the GraphPad Prism 7.02 software program (GraphPad Software Inc, La Jolla, CA). The data were tested for normality using the Shapiro-Wilk normality test and analyzed with two-way analysis of variance, and a correction for multiple comparisons was performed using the Dunnett's test (95% confidence intervals) or a paired *t* test and corrected for multiple comparisons using the Holm-Sidak method, with *α* = 0.05. Error bars indicate S.D. of the mean. We used the following calculation to determine the MO knockdown efficiencies: % knockdown = (1 − ΔΔC~T~) × 100%. All experiments were independently repeated a minimum of two times.

### In Situ Hybridization and Immunohistochemistry. {#s11}

In situ localization of RNA was performed on whole embryos (*n* = 6--10 embryos) at the respective time points as described previously ([@B57]), with the exception that the embryos were permeabilized in 2% hydrogen peroxide in 100% methanol for 20 minutes prior to the initial embryo rehydration. Additionally, probes were hybridized in a final concentration of 10% dextran sulfate. The *sox9b* probe was obtained from [@B12]. The *slincR*, *notch3*, and *adamts3* probes were prepared by PCR amplification from a cDNA template as described in ([@B57]). Dual in situ hybridization and immunohistochemistry samples were performed on the *Tg*(*−2421/+29sox9b:EGFP*~uw2~) *sox9b* reporter line. Embryos were imaged in 3% methylcellulose at room temperature using a Keyence BZ-x700 at 10X with 0.45 aperture and processed with the BZ-x Analyzer software (Keyence, Osaka, Japan).

### Larval Morphology and Behavior Screen. {#s12}

Zebrafish embryos were injected at the 1-cell stage with MOs as described previously and placed into 96-well plates after hatching (∼48--60 hpf), with 24 embryos per injection group. The larval photomotor response assay consisted of 3-minute light and dark alternating periods, for a total of four light-dark transitions, with the first transition representing an acclimation period. The Viewpoint Zebrabox systems (Viewpoint Behavior Technology, Montreal, Canada) were used to analyze photography induced larval locomotor activity in 120 hpf larvae. We followed the protocols and analyzed the overall area under the curve for the last three light-dark cycles compared with control morphants using a Kolmogorov-Smirnov test (*P* \< 0.01) as described in [@B38]. We used 1% alpha to control for type I error inflation rather than controlling the family-wise error rate since we were not correcting for multiple treatments but only for a control and treatment group. Zebrafish were evaluated at 120 hpf for mortality and a suite of 17 physical malformations prior to the viewpoint assay, and embryos identified to be malformed were excluded from the viewpoint data analysis ([@B58]). The morphology data were analyzed using a Fisher's exact test because of its utility of low category counts and because it does not make distributional assumptions (as the *χ*^2^ test does). A Bonferroni multiple comparisons test with control for family-wise error rate was used. The experiment was performed two independent times.

Results {#s13}
=======

 {#s14}

### Molecular Characterization of *SlincR*. {#s15}

We previously performed an RNA-sequencing experiment on 48 hpf whole embryos treated with a strong AHR2 ligand (10 *µ*M B\[*a*\]AQ) to identify the transcriptional networks of protein coding genes that are regulated by AHR2 ([@B19]). Recent advances in our ability to measure RNA transcripts have unveiled lncRNAs as important regulators of gene expression ([@B51]). We mined the data from the [@B19] study in an effort to discover potential lncRNAs that are regulated by AHR2. Using Ensembl's zebrafish genome build Zv9 (release 79) (<http://www.ensembl.org/index.html>), we identified a novel transcript that displayed a log 2-fold increase of 3.2 upon developmental exposure to 10 *µ*M B\[*a*\]AQ. A portion of the novel transcript matched the Ensembl annotated lncRNA *si:Ch1073-384e4.1*, which is located adjacent to the *sox9b* gene on the opposite strand of chromosome 3. The large increase in expression in response to a strong AHR2 ligand and the close proximity to the *sox9b* locus led us to hypothesize that *si:Ch1073-384e4.1* may be regulated by AHR2 and transcriptionally represses *sox9b*. Using 5′ and 3′ rapid amplification of cDNA ends and sequencing analysis, the transcript we identified partially overlaps with the Ensembl annotated lncRNA, *si:Ch1073-384e4.1*. This novel transcript, *sox9b* long intergenic noncoding RNA (*slincR*, Genbank accession number KY085961), shares a 57.6% identity with *si:Ch1073-384e4.1*, with a majority of the similarities found in exon 1 of both transcripts (data not shown). *SlincR* is 466 base pairs in length, contains three exons, and is polyadenylated ([Fig. 1A](#F1){ref-type="fig"}). We were unable to consistently amplify the Ensembl *si:Ch1073-384e4.1* transcript in whole embryos treated with DMSO or B\[*a*\]AQ (data not shown). We note that *si:Ch1073-384e4.1* and *slincR* represent alternative splice variants; however, *slincR* appears to be the most abundant transcript in our fish population. The core AHR element (5′-T/GCGTG-3′) is present in multiple locations in the *slincR* promoter, suggesting *slincR* may be a direct AHR target gene ([Fig. 1A](#F1){ref-type="fig"}). When comparing the zebrafish *slincR*-*sox9b* loci to that of the mouse and human genomes, the spatial arrangement and orientation of potential *slincR* orthologs relative to *Sox9* and the presence of AHR elements in the promoters of the potential orthologs are conserved. Thus, we expect the lncRNA-*Sox9* target relationship to be similar between fish and mammals.

![The *slincR* and *sox9b* locus on chromosome 3, subcellular enrichment, and SHAPE-enhanced prediction of *slincR* secondary structure. (A) Schematic diagram of the *slincR* and *sox9b* locus on chromosome 3 (not to scale). The Ensembl splice variant *si:Ch1073-384e4.1* is not depicted for clarity. (B) Subcellular enrichment of *slincR* in 96 hpf whole embryos. Quantitative real-time PCR was performed on whole embryo, cytoplasmic, and nuclear homogenate samples. *U1* rRNA served as a positive control for nuclear enrichment. Expression values were analyzed with the 2^−ΔΔCT^ method; however, we did not normalize to a reference gene. Results for (B) were statistically analyzed using a paired *t* test and corrected for multiple comparisons using the Holm-Sidak method, with *α* = 0.05. Error bars indicate S.D. of the mean. \*\*\**P* \< 0.001 compared with whole embryo. (C) *SlincR*'s predicted secondary structure. Selective 2′-hydroxyl acylation analyzed by primer extension (SHAPE) was run in triplicate from three independent samples. We normalized the data to be between 0 and 2 and entered the SHAPE reactivities into RNAfold. Unreactive nucleotides (white) participate in canonical base pairs, whereas nucleotides in loops, bulges, and other connecting regions are reactive (blue).](mol.117.108233f1){#F1}

To determine the cellular compartment(s) in which *slincR* is localized, we homogenized ∼50--60 whole embryos at 96 hpf, and then used standard centrifugation fractionation methods, followed by quantitative real-time PCR. There was no significant difference in the relative amounts of *slincR* located in the nucleus versus the cytoplasm ([Fig. 1B](#F1){ref-type="fig"}). Previous reports have demonstrated that quantitative, nucleotide resolution information from a selective 2′-hydroxyl acylation, analyzed by primer extension (SHAPE) experiments, can result in RNA secondary structure predictions with accuracies up to 96%--100% ([@B13]). Briefly, SHAPE allows the probing of RNA secondary structures at single-nucleotide resolution by incubating RNA with *N*-methylisatoic anhydride, which selectively modifies flexible nucleotides and inhibits reverse transcription. The RNA is reverse transcribed, and modified bases are detected via capillary electrophoresis; thus, the SHAPE reactivity data can discriminate between base-paired versus unconstrained or flexible nucleotides in a RNA molecule. We used SHAPE-generated pseudo-free energies, in conjunction with RNAfold, to increase the accuracy of *slincR*'s predicted secondary structure ([Fig. 1C](#F1){ref-type="fig"}). We scaled the data to be between 0 and 2 and entered the SHAPE reactivities into RNAfold. Unreactive nucleotides (white) participate in canonical base pairs, whereas nucleotides in loops, bulges, and other connecting regions are reactive (blue). The tertiary structure is an additional level of information that is required to understand the *slincR* structure-function relationship.

### *SlincR* and *Sox9b* Are Expressed in Adjacent and Overlapping Tissues through Multiple Stages of Development. {#s16}

To better understand endogenous functions of *slincR*, we investigated expression relative to *sox9b* with in situ hybridization in embryos of the wild-type and *sox9b*-eGFP reporter lines over multiple developmental time points (24, 36, 48, 60, and 72 hpf). *SlincR* expression was not detectable at 24 hpf, but starting at 36 hpf expression was evident in the otic vesicle, eye, and jaw/snout region ([Table 1](#T1){ref-type="table"}). *Sox9b*-eGFP and *slincR* were expressed in adjacent and overlapping tissues, including the eye, otic vesicle, and lower jaw region during multiple stages of development ([Fig. 2, A and B](#F2){ref-type="fig"}).

###### 

*SlincR* expression at multiple developmental stages

For each organ or structure 6--10 embryos were scored at each time point.

  *slincR* Expression   Developmental Stage                           
  --------------------- --------------------- ------- ------- ------- -------
                        *hpf*                 *hpf*   *hpf*   *hpf*   *hpf*
  Heart                 N                     N       N       N       N
  Brain                 N                     N       N       N       N
  Otic vesicle          N                     Y       Y       Y       Y
  Eye                   N                     Y       Y       Y       Y
  Jaw/snout             N                     Y       Y       Y       Y
  Pectoral bud/fin      N                     N       N       N       N
  Notochord             N                     N       N       N       N

N, No; Y, Yes.

![*SlincR* and *sox9b*-eGFP are expressed in adjacent and overlapping tissues through multiple stages of development. Lateral (A) and ventral (B) views of dual immunohistochemistry and in situ hybridization samples targeting *sox9b*-eGFP (green) and *slincR* (red) in *sox9b*-eGFP reporter fish at 36 and 48 hpf (*n* = 6--10 embryos). The fish are outlined with a white line, *slincR* expression is outlined with a dotted white line, and the eye is labeled the letter e. The white rectangle represents the magnified area depicted in the inset. Both scale bars represent 100 *µ*m. All experiments were independently repeated a minimum of two times.](mol.117.108233f2){#F2}

### *SlincR* Expression Is AHR2 Dependent. {#s17}

To test our hypothesis that activation of AHR2 results in an increase in *slincR* expression, we used the previously characterized AHR2-null zebrafish line ([@B20]). In 48 hpf wild-type samples, *slincR* expression was significantly increased upon exposure to TCDD ([Fig. 3A](#F3){ref-type="fig"}). However, in AHR2-null animals *slincR* expression was significantly lower compared with wild type at 48 hpf, and no increase in *slincR* expression was observed after developmental exposure to TCDD ([Fig. 3A](#F3){ref-type="fig"}). These results demonstrate that *slincR* expression is increased by exposure to strong AHR ligands (B\[*a*\]AQ and TCDD) and that this induction is an AHR2-dependent event.

![Comparative analysis of AHR2 functional status and *slincR* expression levels and spatial pattern relative to *sox9b*. (A) *SlincR* expression in 48 hpf wild-type 5D (AHR2^+/+^) and AHR2-null (AHR2^−/−^) whole embryos developmentally exposed to 0.1% DMSO (vehicle control) or 1 ng/ml TCDD (*n* = 3 biologic replications). Results were statistically analyzed using the GraphPad Prism 7.02 software. The data were tested for normality using the Shapiro-Wilk normality test, analyzed with two-way analysis of variance, and correction for multiple comparisons was performed using the Dunnett's test (95% confidence intervals). Error bars indicate S.D. of the mean. \*\**P* \< 0.01 compared with DMSO control. ^\#\#^*P* \< 0.01 compared with TCDD control. (B) Dorsal view of dual immunohistochemistry and in situ hybridization samples targeting *sox9b*-eGFP (green) and *slincR* (red) in 48 hpf embryos (*n* = 6--10 embryos). The *Tg*(*−2421/+29sox9b:EGFP*~uw2~) *sox9b* reporter line embryos were developmentally exposed to 0.1% DMSO or 1 ng/ml TCDD. In the TCDD-exposed samples, the regions with increased *slincR* expression had a corresponding decrease in *sox9b*-eGFP expression (white rectangle); e = eye, ov = otic vesicle, p = pectoral fin, fb = forebrain, mb = midbrain, and hb = hindbrain; 100 *µ*m scale bar. All experiments were independently repeated a minimum of two times.](mol.117.108233f3){#F3}

To elucidate the changes in the spatial expression pattern of *slincR* relative to *sox9b* upon AHR2 activation, we exposed the previously characterized *sox9b*-eGFP reporter line *Tg*(*−2421/+29sox9b:EGFP*~uw2~) to 0.1% DMSO or 1 ng/ml TCDD, and performed dual immunohistochemistry and in situ hybridization ([@B47]). Exposure to TCDD displayed decreased *slincR* expression in the brain and increased expression surrounding the otic vesicle, relative to vehicle-exposed samples ([Fig. 3B](#F3){ref-type="fig"}). In the TCDD-exposed samples, the regions with increased *slincR* expression had a corresponding decrease in *sox9b*-eGFP expression ([Fig. 3B](#F3){ref-type="fig"}, white rectangle). The *slincR* expression pattern was similar in all fish examined within each treatment group ([Supplemental Fig. 1](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.117.108233/-/DC1)). Of note, exposure to TCDD also resulted in *slincR* expression in the pectoral fin, which was not seen in DMSO-treated samples ([Fig. 3B](#F3){ref-type="fig"}). Interestingly, the 0.1% DMSO-exposed embryos (vehicle control) displayed increased *slincR* expression in the brain compared with TCDD-exposed embryos. The nonexposed embryos (DMSO or TCDD) did not show any expression of *slincR* in the brain ([Fig. 3](#F3){ref-type="fig"}; [Table 1](#T1){ref-type="table"}). The specific and overlapping expression patterns suggest, but do not prove, interaction between *sox9b* and *slincR*.

### *SlincR* Is Required for Proper Expression Levels and Spatial Pattern of *Sox9b* during Development. {#s18}

To probe the *slincR*-*sox9b* relationship during development antisense knockdown of the endogenous *slincR* and splice variant *si:Ch1073-384e4.1* levels via a splice blocking MO was performed ([Fig. 4A](#F4){ref-type="fig"}). We tested knockdown efficiencies in 48 hpf *slincR* morphants exposed to DMSO or TCDD, which displayed 98% and 81% knockdown efficiencies, respectively ([Fig. 4A](#F4){ref-type="fig"}). In situ hybridization of *slincR* from 48 and 72 hpf ([Fig. 4, C and D](#F4){ref-type="fig"}) control morphant samples exposed to TCDD shows that *slincR* expression is increased in the otic vesicle and the lower jaw/snout region. In situ hybridization also confirmed that *slincR* was barely detected in *slincR* morphants at 48 hpf when treated with DMSO; however, expression of *slincR* was visible in the otic vesicle and lower jaw region in the TCDD-treated samples ([Supplemental Fig. 2](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.117.108233/-/DC1)). Knockdown of *slincR* during early development was not sufficient to rescue the TCDD-induced cartilage malformation phenotype. As previously mentioned, activation of AHR2 by TCDD exposure results in a reduction in the expression of *sox9b* mRNA in craniofacial cartilage, regenerating caudal fin, and heart tissues ([@B5], [@B4]; [@B64]; [@B26]); therefore, we hypothesized that upon exposure to a strong AHR2 ligand, *slincR* increases and is required for the TCDD-mediated reduction in *sox9b* expression. To determine if *slincR* expression was required for the reduction of *sox9b* mRNA in TCDD-treated embryos, we exposed control and *slincR* morphants to 0.1% DMSO or 1 ng/ml TCDD, isolated RNA from whole embryos at 48 hpf, and then measured the relative expression levels of *sox9b* mRNA. In control morphants, exposure to TCDD resulted in a decrease in *sox9b* mRNA levels ([Fig. 4B](#F4){ref-type="fig"}). In contrast, the *slincR* morphants exposed to either DMSO or TCDD displayed a significant increase in *sox9b* expression compared with the control morphants ([Fig. 4B](#F4){ref-type="fig"}). Next, we used in situ hybridization to label *sox9b* mRNA in 48 hpf *slincR* and control morphants exposed 0.1% DMSO or 1 ng/ml TCDD. *SlincR* morphants exposed to DMSO displayed an increase in *sox9b* expression in the otic vesicle and midbrain region compared with DMSO-exposed controls ([Fig. 4E](#F4){ref-type="fig"}). In response to TCDD exposure, *slincR* morphants also displayed an increase in *sox9b* expression in the otic vesicle, lower jaw/snout region, and eye compared with control morphants ([Fig. 4, E and F](#F4){ref-type="fig"}). The data suggest that *slincR* is required for normal *sox9b* expression levels and for the TCDD-mediated reduction in *sox9b* expression.

![Comparative analysis of the relative expression of *slincR* and *sox9* in TCDD-exposed samples. *SlincR* (A) and *sox9b* mRNA (B) quantitative expression in 48 hpf whole embryo *slincR* (*slincR*-MO) and control (ConMO) morphants developmentally exposed to 0.1% DMSO (vehicle control) or 1 ng/ml TCDD. For all quantitative PCR data, expression values were analyzed using the 2^−ΔΔCT^ method. Expression values were normalized to *β*-*actin* and the control morphants served as the calibrator. Samples represent a minimum of three biologic replicates. Results were statistically analyzed using the GraphPad Prism 7.02 software. The data were tested for normality using the Shapiro-Wilk normality test and analyzed with two-way analysis of variance and correction for multiple comparisons was performed using the Dunnett's test (95% confidence intervals). Error bars indicate S.D. of the mean; \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 compared with controls; ^\#\#^*P* \< 0.01 compared with TCDD control. (C--F) dorsal and lateral views of in situ hybridization samples targeting *slincR* (red) and *sox9b* (blue) in 48 hpf (C, E, and F) and 72 hpf (D) embryos (*n* = 6--10 embryos). (C and D) Representative images from control morphants. In the TCDD-exposed samples, *slincR* morphants displayed increased *sox9b* expression patterns compared with controls (white rectangle, which represents the magnified image in the inset). The fish are outlined with a white line; e = eye, ov = otic vesicle, p = pectoral fin, and mb = midbrain; 100 *µ*m scale bar. All experiments were independently repeated a minimum of two times.](mol.117.108233f4){#F4}

Knocking down *slincR* expression altered *sox9b* mRNA transcript levels ([Fig. 4B](#F4){ref-type="fig"}) and spatial expression patterns ([Fig. 4, E and F](#F4){ref-type="fig"}). Next, we determined if the increased expression of *sox9b* observed in the *slincR* morphants had a significant effect on known *sox9b* downstream target genes. We selected genes that were experimentally identified as direct *Sox9* target genes in mammalian primary chondrocytes via a chromatin immunoprecipitation sequencing experiment and examined the orthologous genes in our zebrafish model ([@B45]). In the *slincR* morphants, five out of the nine genes selected had significantly altered relative expression levels at 48 hpf compared with the control ([Fig. 5A](#F5){ref-type="fig"}). The transcripts for *notch3*, *adamts3*, *sfrp2*, and *fgfr3* all had an increase in expression in *slincR* morphants, while *fabp2* displayed a decrease in expression compared with controls. To identify the tissues/regions with altered expression patterns, we used in situ hybridization to label *notch3* and *adamts3* (a protease that cleaves notch) mRNA in 48 hpf *slincR* and control morphants ([Fig. 5, B and C](#F5){ref-type="fig"}). Similar to the *slincR* and *sox9b* expression patterns, *notch3* and *adamts3* are also expressed in the lower jaw/snout region, eye, otic vesicle, and brain at 48 hpf. *SlincR* morphants clearly displayed an increase in *notch3* expression in the midbrain, hindbrain, eye, and pectoral fin and increased *adamts3* expression in the somites of the trunk. These results suggest *slincR* knockdown had a modest but significant impact on the *sox9b* transcriptional regulatory network across multiple tissues during development.

![Comparative analysis of the relative expression of *sox9b* and downstream targets in *slincR* morphants. (A) Quantitative expression levels of *sox9b* and downstream targets in *slincR* and control morphants at 48 hpf. Five out of the nine downstream target genes were significantly different when compared with control morphants. Expression values were analyzed using the 2^−ΔΔCT^ method, normalized to *β*-*actin,* and the control morphants served as the calibrator. Samples represent a minimum of three biologic replicates. Results were statistically analyzed using the GraphPad Prism 7.02 software. The data were tested for normality using the Shapiro-Wilk normality test, analyzed using a paired *t* test, and corrected for multiple comparisons using the Holm-Sidak method, with *α* = 0.05. Error bars indicate S.D. of the mean; \**P* \< 0.05, \*\**P* \< 0.01 compared with controls. Dorsal, ventral, and lateral views of in situ hybridization samples targeting *notch3* (B) and *adamts3* (C) in 48 hpf *slincR* and control morphants (*n* = 6--10 embryos); e = eye, ov = otic vesicle, p = pectoral fin, s = somite, and mb = midbrain; 100 *µ*m scale bar.](mol.117.108233f5){#F5}

### *SlincR* Expression Is Required for Normal Neurologic and/or Locomotor Behavioral Responses to Light. {#s19}

We used an 18 endpoint viability and malformation screen on 120 hpf fish (*n* = 24) to determine the morphologic impact of knocking down *slincR* expression levels early in development. Reduced *slincR* expression levels during development did not result in any statistically significant malformation incidences at 120 hpf ([Fig. 6A](#F6){ref-type="fig"}). Morphologically, the *slincR* morphants were indistinguishable from control morphants, with both appearing developmentally normal. To evaluate the effect of reduced *slincR* expression levels on neurologic and locomotor behavior, 120 hpf fish (*n* = 23) were subjected to a light-dark photometer assay that reported hyperactive or hypoactive swimming ([@B38]). The morphologic and behavioral assays were conducted on the same 120 hpf fish. Reducing *slincR* expression during early development resulted in a modest but significantly hypoactive photomotor response (*P* \< 0.01; −14.04% difference in mean area under the curve compared with controls) ([Fig. 6B](#F6){ref-type="fig"}). The larval photomotor response assay suggested that reduced *slincR* expression significantly affected some aspect(s) of neuromuscular and/or sensory system development.

![Phenotypic analysis of reduction in *slincR* expression during early development. (A) An 18-endpoint morphologic screen in *slincR* and control morphants at 120 hpf (*n* = 24). No significant malformations were observed in the *slincR* morphants. Control and *slincR* morphant evaluations were completed in a binary notation (present/absent) and statistically compared using Fisher's exact test at *P* \< 0.05 for each endpoint. (B) Larval photomotor response (LPR) in control and *slincR* morphants at 120 hpf (*n* = 23) using the Viewpoint Zebrabox systems. *SlincR* morphants displayed a hypoactive response (*P* \< 0.01), with −14.04% difference of the mean area under the curve when compared with controls. The LPR assay consisted of 3 minutes of light and dark alternating periods, for a total of four light-dark transitions, with the first transition representing an acclimation period. The black and white bar along the *y*-axis indicates the 3 minutes of light (white) and dark (black) alternating periods. Larval zebrafish at this developmental stage display increased locomotion during periods of darkness. The overall area under the curve was analyzed for the last three light-dark cycles compared with control morphants using a Kolmogorov-Smirnov test (*P* \< 0.01). All experiments were independently repeated a minimum of two times.](mol.117.108233f6){#F6}

Discussion {#s20}
==========

The AHR is a key mediator of cell signaling during development and homeostasis, as well as in response to environmental pollutant exposure ([@B24]). Dysregulation of AHR has been associated with multiple diseases, such as coronary artery and prostrate disease ([@B61]; [@B52]; [@B29]). In humans, haploinsufficiency of *SOX9* is associated with organ malformations, while *SOX9* duplication results in male-to-female sex reversal ([@B28]). Increased or ectopic expression of *SOX9* is associated with liver fibrosis and several different cancer types ([@B50]; [@B43]). *Sox9* plays an important role during embryonic development, determining cell fate in cells derived from all three germ layers ([@B30]). Recent work has also suggested a role for *Sox9* in cell maintenance and specification during adulthood ([@B17]; [@B7]). Our study examined the relationship between AHR2, a novel lncRNA (*slincR*), and *sox9b* using the zebrafish model, to gain insight into how inappropriate AHR2 activation leads to a reduction in *sox9b* expression and impairs cartilage and heart development. Understanding the layers of regulation downstream from AHR will aid in our understanding of the role of AHR in development and how xenobiotic activation or misexpression of AHR leads to negative phenotypic consequences.

The results of this study suggest that *slincR* expression is AHR2 dependent and is required for proper *sox9b* expression levels during normal development. *Sox9b* is hypothesized to have a causal role in the AHR2 toxicity signaling pathway since antisense knockdown of *sox9b* was sufficient to phenocopy TCDD-induced craniofacial cartilage malformations ([@B64]). Additionally, a *sox9b* mutant partially phenocopied AHR2-activated cardiac malformations in zebrafish, indicating *sox9b* and other unidentified genes are responsible for the heart malformation phenotype ([@B26]). In the absence of functional AHR2, *slincR* expression was significantly lower than in wild-type fish and did not increase in response to TCDD exposure. Additionally, when we knocked down the levels of *slincR* and activated the AHR2 pathway, we did not see a reduction in *sox9b* expression. These results place *slincR* as an intermediate between AHR2 activation and the reduction of *sox9b* expression in the AHR signaling pathway.

In support of a relationship between *slincR* and *sox9b*, *slincR* was shown to be expressed in adjacent and overlapping tissues and to have a significant impact on the expression of *sox9b* and several of its downstream targets. Our data demonstrate that the *slincR* transcript functions as an RNA macromolecule and acts locally (in *cis*) on chromosome 3 to regulate the spatial and relative expression levels of *sox9b*. We detected *slincR* expression in tissues that have reported essential functions for *sox9*, including the otic vesicle, eye, and brain ([@B65]; [@B53]; [@B66]). Upon TCDD exposure, *sox9b* expression is reduced in zebrafish heart ventricles ([@B26]). We did not detect *slincR* in the developing heart, which suggests there are tissue-specific mechanisms of *sox9b* regulation. In *slincR* morphants, we detected significant differences in the relative expression levels of *sox9b* and known *Sox9* targets that were previously identified in mammalian primary chondrocytes. Several of the significantly altered genes are also known to converge with *Sox9* signaling in multiple organs through development, including *fgf3*, *sfrp2* (Wnt ligand), and *notch3* ([@B30]). In *slincR* morphants, *notch3* and *adamts3* (protease that cleaves notch receptors) both had a small but significant increase in their relative expression and displayed altered spatial expression patterns. In cartilage development, notch signaling has been shown to regulate the onset of chondrocyte maturation in a *Sox9*-dependent manner and to negatively regulate chondrocyte differentiation by suppressing *Sox9* transcription ([@B39]). Evidence from mouse chondrogenic ATDC5 cells suggests that notch signaling initially induces *Sox9* expression, but prolonged notch signaling leads to suppression of *Sox9* transcription via secondary effectors ([@B11]). Notch signaling in ectoderm-derived cells, which includes the central nervous system, otic placode, and eye, was shown to induce *sox9* expression for stem cell maintenance, astrogliogenesis, and eye development ([@B42]; [@B66]).

In our study, reducing the expression of *slincR* during early stages of development did not result in overt malformations at the organismal level. These results are not surprising for a number of reasons. In zebrafish, a phenotypic analysis of 1,216 non-sense and essential splice mutations resulted in 87.58% of mutations linked to no observable morphologic or behavioral phenotype. This implies that the zebrafish genome operates under a high degree of redundancy and may indicate the presence of genetic compensatory networks ([@B33]). Additionally, we hypothesize that *slincR* expression is downstream from AHR2, and the AHR2-null line does not display overt malformations during embryonic development ([@B20]).

A reduction in *slincR* expression during early stages of embryonic development resulted in altered photomotor responses. We also detected *slincR* expression in the brain of DMSO- and TCDD-exposed embryos. DMSO is known to cause membrane destabilization and has been used to facilitate administration of drugs that do not normally cross the blood brain barrier ([@B46]; [@B36]). *SlincR* expression in the brain was not seen in DMSO-exposed AHR2-null mutants. It is plausible that exposure to DMSO decreased the integrity of the blood brain barrier, allowing an unidentified ligand to activate the AHR2 receptor in the brain. *SlincR* morphants also displayed altered *sox9b* and *notch3* expression patterns in the brain. Mammalian and zebrafish models have identified a large number of lncRNAs that exhibit neuronal-specific expression, which suggests a role for lncRNAs in the establishment and maintenance of the vertebrate nervous system ([@B44]; [@B32]). In the adult zebrafish, the largest number of tissue-specific lncRNA transcripts was expressed in the brain ([@B32]). In mammals and zebrafish, *Sox9* is expressed in the brain and is a conserved transcription factor involved in central nervous system development ([@B15]; [@B53]; [@B42]; [@B47]).

Our study did not address how *slincR* expression leads to reduced *sox9b* mRNA levels. Future studies will be conducted to establish the mechanism of *slincR*-induced *sox9b* suppression. A limitation of this study was our inability to maintain *slincR* repression during later stages of development to determine late-stage phenotypic consequences. This prevented us from determining *slincR*'s contribution to TCDD-induced toxicity phenotypes, such as cartilage malformation. Knocking down *slincR* during early development is not sufficient to rescue the TCDD-induced cartilage malformation phenotype. In future studies, we will use a CRISPR/Cas9-generated *slincR* knockout line and increase the resolution by examining the tissues and cells in which *slincR* is expressed.

In summary, we identified an AHR2-dependent novel lncRNA (*slincR*) that is required for proper *sox9b* expression during normal development and in response to a strong AHR ligand. *SlincR* acts in *cis* to regulate *sox9b* expression; however, additional experiments are required to determine the mechanism of *slincR*-induced reduction of *sox9b*. In concordance with other lncRNA studies, *slincR* expression was tissue specific and was not required for normal morphologic development (measured at the organismal level). *SlincR* was required for normal photomotor behavior in the larval stage, suggesting a role for *slincR* in neuromuscular and/or sensory system development. This study adds to the growing body of research demonstrating important roles of lncRNAs during neural development, and adds to our understanding of how AHR signaling intersects with the *sox9b* network to mediate developmental effects of environmental pollutants.
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